Fabry Disease Treatment Market Size

Fabry Disease Treatment Market Size

Fabry Disease Treatment Market was valued at over USD 1.7 billion in 2021. Driven by the increasing burden of heart and other organ-related problems in late-onset Fabry disease patients, the industry is expected to depict a CAGR of over 8% from 2022 to 2030

To get key market trends

  Download Free Sample

The incidence rate of Fabry disease continues to rise worldwide. Chaperone and ERT (enzyme replacement therapy) are common therapeutic approaches designed to improve the clinical symptoms of patients with this genetic disease. The type 1 classic and late-onset Fabry disease symptoms, which are three times to ten times more common than the classic type, are becoming prevalent, especially among men.

Based on recent research, Fabry disease is also emerging as the second most common genetic metabolic storage disease, often resulting in progressive organ damage or failure and premature death. Heart problems in patients with Fabry disease include the enlargement of heart muscles due to extra effort required to pump blood. This condition is common among patients with late-onset Fabry disease aged 40 years or above. The rapidly aging population is thus expected to accelerate Fabry disease diagnosis and treatment, stimulating industry statistics.